caffeine has been researched along with Recrudescence in 42 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This prospective controlled study was aimed at evaluating the efficacy of caffeine in treating recurrent idiopathic apnea in the premature infant." | 9.05 | The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. ( Blin, MC; Couchard, M; De Gamarra, E; Dreyfus-Brisac, C; Flouvat, B; Moriette, G; Murat, I; Relier, JP, 1981) |
| "An increased intracellular shift of potassium and increased loss of potassium in urine due to the diuretic action have been suggested to be the causes of caffeine-induced hypokalemia." | 8.02 | Caffeine-induced hypokalemia: a case report. ( Han, MJ; Hwang, JH; Kim, SH; Shin, JH, 2021) |
| "A retrospective review was done to identify infants who received caffeine therapy for RSV-associated apnea." | 7.70 | Caffeine in the treatment of apnea associated with respiratory syncytial virus infection in neonates and infants. ( Tobias, JD, 2000) |
| "Incidence, healing rate, and recurrence rate correlate with the number of cigarettes smoked." | 6.37 | [Effects of nicotine, alcohol and caffeine on the incidence, healing and recurrence rate of peptic ulcer]. ( Holstege, A, 1987) |
| "Caffeine treatment augmented A1AR expression on microglia, with ensuing reduction of EAE severity, which was further enhanced by concomitant treatment with the A1AR agonist, adenosine amine congener." | 5.32 | A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. ( Henry, S; Noorbakhsh, F; Power, C; Schnermann, J; Tsutsui, S; Warren, K; Winston, BW; Yong, VW, 2004) |
| "This prospective controlled study was aimed at evaluating the efficacy of caffeine in treating recurrent idiopathic apnea in the premature infant." | 5.05 | The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. ( Blin, MC; Couchard, M; De Gamarra, E; Dreyfus-Brisac, C; Flouvat, B; Moriette, G; Murat, I; Relier, JP, 1981) |
| "An increased intracellular shift of potassium and increased loss of potassium in urine due to the diuretic action have been suggested to be the causes of caffeine-induced hypokalemia." | 4.02 | Caffeine-induced hypokalemia: a case report. ( Han, MJ; Hwang, JH; Kim, SH; Shin, JH, 2021) |
| " Recurrent acute uncomplicated urinary tract infection patients who also have chronic constipation or consume caffeine have lower quality of life than those who do not." | 3.88 | Premenopausal women with recurrent urinary tract infections have lower quality of life. ( Chen, SL; Ennis, SS; Guo, H; Raman, L; Tambyah, PA; Tiong, HY, 2018) |
| " Following initial improvement, she developed delayed rhabdomyolysis then haloperidol-induced neuroleptic malignant syndrome, which was treated with a total of 50 mg." | 3.78 | Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene. ( Hawryluck, LA; Kraeva, N; Riazi, S; Russell, T; Steel, AC, 2012) |
| "We have examined the modulation of radiosensitivity by using caffeine in two human sarcoma cell lines both with a p53 mutation (US8-93 and LMS6-93)." | 3.71 | Loss of G2/M arrest correlates with radiosensitization in two human sarcoma cell lines with mutant p53. ( Bache, M; Bartel, F; Dunst, J; Meye, A; Pigorsch, S; Rath, FW; Schmidt, H; Taubert, H; Würl, P, 2001) |
| "A retrospective review was done to identify infants who received caffeine therapy for RSV-associated apnea." | 3.70 | Caffeine in the treatment of apnea associated with respiratory syncytial virus infection in neonates and infants. ( Tobias, JD, 2000) |
| "In this double-blind, double-dummy, randomised, parallel group, multicentre study, the efficacy of dosing and re-dosing of a fixed combination of indomethacin, prochlorperazine and caffeine (Indoprocaf) was compared with encapsulated sumatriptan in the acute treatment of two migraine attacks." | 2.73 | Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, mu ( Cerbo, R; Del Bene, E; Ferrari, A; Genco, S; Grazioli, I; Martelletti, P; Nappi, G; Pinessi, L; Sandrini, G; Sarchielli, P; Tamburro, P; Uslenghi, C; Zanchin, G, 2007) |
| "One hundred twelve patients with migraine with or without aura according to the diagnostic criteria of the International Headache Society were randomized to treat 2 migraine attacks with a fixed combination of indomethacin, prochlorperazine, and caffeine and 2 migraine attacks with sumatriptan." | 2.71 | Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. ( Aloisio, A; Del Bianco, P; Di Monda, V; Fonzari, M; Grazioli, I; Nicolodi, M; Sicuteri, F; Uslenghi, C; Vecchiet, L, 2003) |
| "Sumatriptan was significantly more effective than Cafergot at reducing the intensity of headache from severe or moderate to mild or none; 66% (145/220) of those treated with sumatriptan improved in this way by 2 h, compared with 48% (118/246) of those treated with Cafergot (p less than 0." | 2.67 | A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. ( , 1991) |
| "Incidence, healing rate, and recurrence rate correlate with the number of cigarettes smoked." | 2.37 | [Effects of nicotine, alcohol and caffeine on the incidence, healing and recurrence rate of peptic ulcer]. ( Holstege, A, 1987) |
| "Studies of substance use in first episode psychosis patients do not frequently assess non-pathological substance consumption among patients, but rather the prevalence of substance abuse or dependence disorders." | 1.43 | Differential effects of sex on substance use between first episode psychosis patients and healthy people. ( Baños, I; Barajas, A; Del Cacho, N; Dolz, M; Huerta-Ramos, E; Núñez, C; Ochoa, S; Sánchez, B; Usall, J, 2016) |
| "The risks of repeated miscarriage were increased for women aged > or = 35 years (adjusted OR 2." | 1.33 | Risks of repeated miscarriage. ( Cnattingius, S; George, L; Granath, F; Johansson, AL; Olander, B, 2006) |
| "The sequence and timing of taking migraine medications, whether prescription or over-the-counter, and the patient's response to their treatment, is unknown." | 1.33 | Acute migraine treatment: patterns of use and satisfaction in a clinical population. ( Hopkins, M; Malik, SN; Silberstein, SD; Young, WB, 2006) |
| "Caffeine treatment augmented A1AR expression on microglia, with ensuing reduction of EAE severity, which was further enhanced by concomitant treatment with the A1AR agonist, adenosine amine congener." | 1.32 | A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. ( Henry, S; Noorbakhsh, F; Power, C; Schnermann, J; Tsutsui, S; Warren, K; Winston, BW; Yong, VW, 2004) |
| "Regulation of muscle contraction is abnormal in Thoroughbreds with RER." | 1.30 | Abnormal regulation of muscle contraction in horses with recurrent exertional rhabdomyolysis. ( Balog, EM; Gallant, EM; Lentz, LR; Mickelson, JR; Valberg, SJ, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (21.43) | 18.7374 |
| 1990's | 8 (19.05) | 18.2507 |
| 2000's | 13 (30.95) | 29.6817 |
| 2010's | 10 (23.81) | 24.3611 |
| 2020's | 2 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Furtado, RHM | 1 |
| Venkateswaran, RV | 1 |
| Nicolau, JC | 1 |
| Gurmu, Y | 1 |
| Bhatt, DL | 1 |
| Storey, RF | 1 |
| Steg, PG | 1 |
| Magnani, G | 1 |
| Goto, S | 1 |
| Dellborg, M | 1 |
| Kamensky, G | 1 |
| Isaza, D | 1 |
| Aylward, P | 1 |
| Johanson, P | 1 |
| Bonaca, MP | 1 |
| Han, MJ | 1 |
| Kim, SH | 1 |
| Shin, JH | 1 |
| Hwang, JH | 1 |
| Rodríguez-Artalejo, F | 1 |
| López-García, E | 1 |
| Ennis, SS | 1 |
| Guo, H | 1 |
| Raman, L | 1 |
| Tambyah, PA | 1 |
| Chen, SL | 1 |
| Tiong, HY | 1 |
| Peerapen, P | 1 |
| Thongboonkerd, V | 1 |
| Regier, PS | 1 |
| Claxton, AB | 1 |
| Zlebnik, NE | 1 |
| Carroll, ME | 1 |
| Laskowski, LK | 1 |
| Henesch, JA | 1 |
| Nelson, LS | 1 |
| Hoffman, RS | 1 |
| Smith, SW | 1 |
| Núñez, C | 1 |
| Ochoa, S | 1 |
| Huerta-Ramos, E | 1 |
| Baños, I | 1 |
| Barajas, A | 1 |
| Dolz, M | 1 |
| Sánchez, B | 1 |
| Del Cacho, N | 1 |
| Usall, J | 1 |
| Tibrewal, P | 1 |
| Dhillon, R | 1 |
| Henderson-Smart, DJ | 1 |
| De Paoli, AG | 1 |
| Menkes, DB | 1 |
| Russell, T | 1 |
| Riazi, S | 1 |
| Kraeva, N | 1 |
| Steel, AC | 1 |
| Hawryluck, LA | 1 |
| Di Monda, V | 1 |
| Nicolodi, M | 1 |
| Aloisio, A | 1 |
| Del Bianco, P | 1 |
| Fonzari, M | 1 |
| Grazioli, I | 2 |
| Uslenghi, C | 2 |
| Vecchiet, L | 1 |
| Sicuteri, F | 1 |
| Tsutsui, S | 1 |
| Schnermann, J | 1 |
| Noorbakhsh, F | 1 |
| Henry, S | 1 |
| Yong, VW | 1 |
| Winston, BW | 1 |
| Warren, K | 1 |
| Power, C | 1 |
| Dranchak, PK | 1 |
| Valberg, SJ | 3 |
| Onan, GW | 1 |
| Gallant, EM | 3 |
| MacLeay, JM | 1 |
| McKenzie, EC | 1 |
| De La Corte, FD | 1 |
| Ekenstedt, K | 1 |
| Mickelson, JR | 3 |
| Woodside, DB | 1 |
| Colton, P | 1 |
| Staab, R | 1 |
| Schreiber, M | 1 |
| Sutandar-Pinnock, K | 1 |
| Poynter, B | 1 |
| Sacevich, T | 1 |
| George, L | 1 |
| Granath, F | 1 |
| Johansson, AL | 1 |
| Olander, B | 1 |
| Cnattingius, S | 1 |
| Malik, SN | 1 |
| Hopkins, M | 1 |
| Young, WB | 1 |
| Silberstein, SD | 1 |
| Sandrini, G | 1 |
| Cerbo, R | 1 |
| Del Bene, E | 1 |
| Ferrari, A | 1 |
| Genco, S | 1 |
| Martelletti, P | 1 |
| Nappi, G | 1 |
| Pinessi, L | 1 |
| Sarchielli, P | 1 |
| Tamburro, P | 1 |
| Zanchin, G | 1 |
| Murat, I | 1 |
| Moriette, G | 1 |
| Blin, MC | 1 |
| Couchard, M | 1 |
| Flouvat, B | 1 |
| De Gamarra, E | 1 |
| Relier, JP | 1 |
| Dreyfus-Brisac, C | 1 |
| Domínguez-Rojas, V | 1 |
| de Juanes-Pardo, JR | 1 |
| Astasio-Arbiza, P | 1 |
| Ortega-Molina, P | 1 |
| Gordillo-Florencio, E | 1 |
| Beale, MD | 1 |
| Pritchett, JT | 1 |
| Kellner, CH | 1 |
| Anaya Ordóñez, S | 1 |
| Matas Hoces, A | 1 |
| Self, DW | 1 |
| Barnhart, WJ | 1 |
| Lehman, DA | 1 |
| Nestler, EJ | 1 |
| Maizels, M | 1 |
| Lentz, LR | 1 |
| Balog, EM | 1 |
| Ward, TL | 1 |
| Tobias, JD | 1 |
| Bulaj, ZJ | 1 |
| Franklin, MR | 1 |
| Phillips, JD | 1 |
| Miller, KL | 1 |
| Bergonia, HA | 1 |
| Ajioka, RS | 1 |
| Griffen, LM | 1 |
| Guinee, DJ | 1 |
| Edwards, CQ | 1 |
| Kushner, JP | 1 |
| Freeman, D | 1 |
| Randall, DB | 1 |
| Bache, M | 1 |
| Pigorsch, S | 1 |
| Dunst, J | 1 |
| Würl, P | 1 |
| Meye, A | 1 |
| Bartel, F | 1 |
| Schmidt, H | 1 |
| Rath, FW | 1 |
| Taubert, H | 1 |
| Mauskop, A | 1 |
| Tondo, L | 1 |
| Rudas, N | 1 |
| Bairam, A | 1 |
| Vert, P | 1 |
| Migneco, G | 1 |
| Mascarella, A | 1 |
| Tripi, S | 1 |
| La Cascia, C | 1 |
| Navetta, A | 1 |
| Bucher, HU | 1 |
| Duc, G | 1 |
| Holstege, A | 1 |
| James, JE | 1 |
| Paull, I | 1 |
| Cameron-Traub, E | 1 |
| Miners, JO | 1 |
| Lelo, A | 1 |
| Birkett, DJ | 1 |
| Shuster, J | 1 |
| Finlayson, B | 1 |
| Scheaffer, RL | 1 |
| Sierakowski, R | 1 |
| Zoltek, J | 1 |
| Dzegede, S | 1 |
| Friedman, AP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| [NCT01066728] | Phase 2/Phase 3 | 87 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
4 reviews available for caffeine and Recrudescence
| Article | Year |
|---|---|
Coffee Consumption and Cardiovascular Disease: A Condensed Review of Epidemiological Evidence and Mechanisms.
Topics: Aged; Blood Pressure; Caffeine; Cardiovascular Diseases; Coffee; Female; Humans; Hypertension; Male; | 2018 |
Caffeine in Kidney Stone Disease: Risk or Benefit?
Topics: Beverages; Caffeine; Carbonated Beverages; Coffee; Diet; Diuretics; Dose-Response Relationship, Drug | 2018 |
Prophylactic methylxanthine for prevention of apnoea in preterm infants.
Topics: Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Humans; Hypoxia; Infant, Newborn; I | 2010 |
[Effects of nicotine, alcohol and caffeine on the incidence, healing and recurrence rate of peptic ulcer].
Topics: Caffeine; Ethanol; Humans; Nicotine; Peptic Ulcer; Recurrence; Smoking; Wound Healing | 1987 |
7 trials available for caffeine and Recrudescence
| Article | Year |
|---|---|
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Beverages; Caffeine; Double-Blind Method; Dual Anti-Platelet Therapy; Dyspnea; Female | 2020 |
Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Caffeine; Central Nervou | 2003 |
Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, mu
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Caffeine; Double-Blind Method; Drug Combination | 2007 |
The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Prospective Studies; Recurren | 1981 |
[Sumatriptan in the treatment of acute migraine: its role in primary health care].
Topics: Acute Disease; Administration, Oral; Algorithms; Aspirin; Caffeine; Double-Blind Method; Drug Therap | 1994 |
A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group.
Topics: Administration, Oral; Adult; Aged; Caffeine; Double-Blind Method; Drug Combinations; Electrocardiogr | 1991 |
Does caffeine prevent hypoxaemic episodes in premature infants? A randomized controlled trial.
Topics: Blood Gas Monitoring, Transcutaneous; Bradycardia; Caffeine; Citrates; Clinical Trials as Topic; Dou | 1988 |
31 other studies available for caffeine and Recrudescence
| Article | Year |
|---|---|
Caffeine-induced hypokalemia: a case report.
Topics: Adult; Caffeine; Coffee; Diet Therapy; Diuretics; Drinking Behavior; Fluid Therapy; Humans; Hypokale | 2021 |
Premenopausal women with recurrent urinary tract infections have lower quality of life.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Caffeine; Coffee; Comorbidity; Constipation; Feeding Be | 2018 |
Cocaine-, caffeine-, and stress-evoked cocaine reinstatement in high vs. low impulsive rats: treatment with allopregnanolone.
Topics: Animals; Behavior, Addictive; Caffeine; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; D | 2014 |
Start me up! Recurrent ventricular tachydysrhythmias following intentional concentrated caffeine ingestion.
Topics: Adrenergic beta-Antagonists; Caffeine; Dietary Supplements; Electric Countershock; Electrocardiograp | 2015 |
Differential effects of sex on substance use between first episode psychosis patients and healthy people.
Topics: Adolescent; Adult; Alcohol Drinking; Caffeine; Cannabis; Comorbidity; Female; Humans; Illicit Drugs; | 2016 |
Caffeine induced psychotic exacerbation.
Topics: Caffeine; Humans; Male; Middle Aged; Recurrence; Schizophrenia | 2011 |
Transient psychotic relapse temporally related to ingestion of an "energy drink".
Topics: Adult; Beverages; Caffeine; Central Nervous System Stimulants; Humans; Male; Psychoses, Substance-In | 2011 |
Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene.
Topics: Anesthetics, Inhalation; Antipsychotic Agents; Body Temperature; Caffeine; Central Nervous System St | 2012 |
A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Animals; Caffeine; Disease Models, Animal; Disease Progre | 2004 |
Inheritance of recurrent exertional rhabdomyolysis in thoroughbreds.
Topics: Anesthetics, Inhalation; Animals; Biopsy; Caffeine; Case-Control Studies; Central Nervous System Sti | 2005 |
Weight restoration in a patient with anorexia nervosa on dialysis.
Topics: Adult; Anorexia Nervosa; Aspirin; Barbiturates; Body Mass Index; Body Weight; Caffeine; Combined Mod | 2005 |
Risks of repeated miscarriage.
Topics: Abortion, Spontaneous; Adult; Caffeine; Case-Control Studies; Cotinine; Dietary Supplements; Female; | 2006 |
Acute migraine treatment: patterns of use and satisfaction in a clinical population.
Topics: Acetaminophen; Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caffein | 2006 |
Analgesic abuse and the kidney.
Topics: Aged; Analgesics; Aspirin; Caffeine; Codeine; Drug Combinations; Humans; Kidney; Kidney Diseases; Ki | 1980 |
Spontaneous abortion in a hospital population: are tobacco and coffee intake risk factors?
Topics: Abortion, Spontaneous; Adult; Age Factors; Alcohol Drinking; Caffeine; Case-Control Studies; Coffee; | 1994 |
Supraventricular tachycardia in a patient receiving ECT, clozapine, and caffeine.
Topics: Affective Disorders, Psychotic; Aged; Caffeine; Clozapine; Combined Modality Therapy; Depressive Dis | 1994 |
Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists.
Topics: Animals; Behavior, Addictive; Behavior, Animal; Benzazepines; Caffeine; Cocaine; Dopamine Agonists; | 1996 |
Limitations of acetaminophen, aspirin, and caffeine in alleviating migraine.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caffeine; | 1998 |
Abnormal regulation of muscle contraction in horses with recurrent exertional rhabdomyolysis.
Topics: Anesthetics, Inhalation; Animals; Biopsy; Caffeine; Central Nervous System Stimulants; Female; Halot | 1999 |
Calcium regulation by skeletal muscle membranes of horses with recurrent exertional rhabdomyolysis.
Topics: Animals; Biopsy; Caffeine; Calcium; Calcium-Transporting ATPases; Dose-Response Relationship, Drug; | 2000 |
Caffeine in the treatment of apnea associated with respiratory syncytial virus infection in neonates and infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Critical Care; Data Interpretation, Statistical; | 2000 |
Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda.
Topics: Administration, Cutaneous; Adult; Caffeine; Case-Control Studies; Cytochrome P-450 CYP1A2; Estrogen | 2000 |
Stress fracture of the foot secondary to osteoporosis: an atypical presentation.
Topics: Adult; Caffeine; Female; Foot Bones; Fractures, Stress; Humans; Osteoporosis; Recurrence | 2001 |
Loss of G2/M arrest correlates with radiosensitization in two human sarcoma cell lines with mutant p53.
Topics: Adenocarcinoma; Alleles; Apoptosis; Blotting, Western; Caffeine; Cell Survival; Combined Modality Th | 2001 |
Clinical features of withdrawal headache following overuse of triptans and other headache drugs.
Topics: Analgesics; Caffeine; Causality; Codeine; Drug Overdose; Headache; Headache Disorders; Humans; Prosp | 2002 |
The course of a seasonal bipolar disorder influenced by caffeine.
Topics: Bipolar Disorder; Caffeine; Chlorpromazine; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 1991 |
Low-dose doxapram for apnoea of prematurity.
Topics: Apnea; Caffeine; Doxapram; Drug Therapy, Combination; Humans; Infant, Newborn; Infant, Premature, Di | 1986 |
[Cytolytic episodes during cirrhosis].
Topics: Antipyrine; Anxiety Disorders; Barbiturates; Caffeine; Cholestasis; Drug Therapy, Combination; Femal | 1986 |
Biochemical validation of self-reported caffeine consumption during caffeine fading.
Topics: Adult; Caffeine; Coffee; Female; Humans; Male; Middle Aged; Recurrence; Self Disclosure; Substance-R | 1988 |
Primary liquid intake and urinary stone disease.
Topics: Adolescent; Adult; Animals; Beer; Beverages; Caffeine; Cattle; Drinking; Epidemiologic Methods; Hern | 1985 |
Migraine headaches.
Topics: Caffeine; Contraceptives, Oral; Cyproheptadine; Diagnosis, Differential; Diuretics; Drug Combination | 1972 |